[1] |
Nigam JS, Nishit, Kumar T, et al. Anorectal melanoma-brownish black mass not always a hemorrhoid [J]. J Gastrointest Cancer, 2022, 53(3): 825-829.
|
[2] |
中国抗癌协会,中国抗癌协会大肠癌专业委员会.中国恶性肿瘤整合诊治指南-肛管癌部分[J/OL].中华结直肠疾病电子杂志, 2022, 11(1): 13-17.
|
[3] |
王锡山.肛管直肠恶性黑色素瘤诊治指南解读[J/CD].中华结直肠疾病电子杂志, 2015, 4(2): 15-17.
|
[4] |
中国临床肿瘤学会指南工作委员会.黑色素瘤诊疗指南2022[M].北京:人民卫生出版社, 2022.
|
[5] |
曹龙磊,周启昌,于杰,等.老年肛管直肠恶性黑色素瘤、腺癌伴Paget病与鳞癌的复合癌一例[J].中华胃肠外科杂志, 2016, 19(12): 1434-1435.
|
[6] |
Slingluff CLJr, Vollmer RT, Seigler HF. Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients [J]. Surgery, 1990, 107(1): 1-9.
|
[7] |
Pessaux P, Pocard M, Elias D, et al. Surgical management of primary anorectal melanoma [J]. Br J Surg, 2004, 91(9): 1183-1187.
|
[8] |
陈勇,叶红.肛管直肠恶性黑色素瘤6例临床病理学分析[J].肿瘤学杂志, 2017, 23(10): 928-930.
|
[9] |
魏雪静,张彦宁,徐瑞,等.原发性消化道黑色素瘤14例临床病理分析[J].临床与实验病理学杂志, 2021, 37(6): 655-659.
|
[10] |
邹振玉,刘海亮,孙培鸣,等.肛管直肠恶性黑色素瘤34例治疗与预后分析[J].中华胃肠外科杂志, 2013, 16(5): 459-462.
|
[11] |
Tracey EH, Vij A. Updates in melanoma [J]. Dermatol Clin, 2019, 37(1): 73-82.
|
[12] |
李燕,徐青,余静,等.肛管直肠原发性恶性黑色素瘤的CT和MRI诊断:2例报告并文献复习[J].医学影像学杂志, 2016, 26(1): 153-156.
|
[13] |
Puglisi R, Bellenghi M, Pontecorvi G, et al. Biomarkers for diagnosis, prognosis and response to immunotherapy in melanoma[J]. Cancers (Basel), 2021, 13(12): 2875.
|
[14] |
Eisenstein A, Gonzalez EC, Raghunathan R, et al. Emerging biomarkers in cutaneous melanoma[J]. Mol Diagn Ther, 2018, 22(2): 203-218.
|
[15] |
栾立鹏,陈俊杰,顾闻,等.直肠肛管恶性黑色素瘤1例报告[J].中国血液流变学杂志, 2019, 29(3): 277-280, 302.
|
[16] |
张森,高枫,陈利生,等.直肠肛管恶性黑色素瘤的临床特征分析[J].中华胃肠外科杂志, 2005, 8(4): 309-311.
|
[17] |
Iddings DM, Fleisig AJ, Chen SL, et al. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? [J]. Ann Surg Oncol, 2010, 17(1): 40-44.
|
[18] |
Jaiswal BS, Janakiraman V, Kljavin NM, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors[J]. PLoS One, 2009, 4(5): e5717.
|
[19] |
Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma [J]. J Transl Med, 2012, 10: 85.
|
[20] |
O'Donnell JS, Long GV, Scolyer RA, et al. Resistance to PD1/PDL1 checkpoint inhibition[J]. Cancer Treat Rev, 2017, 52: 71-81.
|